RecruitingNot ApplicableNCT07127458

Anxiety and Depression in Adolescent PCOS

Prevalence of Anxiety and Depression in Adolescents With Polycystic Ovary Syndrome

Sponsor

Ege University

Enrollment

42 participants

Start Date

Aug 17, 2025

Study Type

INTERVENTIONAL

Conditions

PCOS (Polycystic Ovary Syndrome)

Summary

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in adolescent females, often accompanied by psychological symptoms such as anxiety and depression. These conditions are frequently underdiagnosed and untreated. This study aims to determine the prevalence of anxiety and depression in adolescents with PCOS and to assess changes following oral contraceptive use.

Eligibility

Sex: FEMALEMin Age: 15 YearsMax Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at anxiety and depression in teenage girls who have polycystic ovary syndrome (PCOS) — a hormonal condition that affects the ovaries — to better understand the mental health impact of the diagnosis. **You may be eligible if...** - You are between 15 and 19 years old - You have been diagnosed with adolescent PCOS **You may NOT be eligible if...** - You have severe difficulty with reading or understanding - You have severe hearing impairment - You are currently using hormone therapy - You have a virilizing tumor (a rare tumor that produces male hormones) - You have been diagnosed with a major psychiatric condition such as schizophrenia, bipolar disorder, or dissociative disorder Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAdolescent PCOS group receiving oral contraceptives

Participants diagnosed with polycystic ovary syndrome (PCOS) during adolescence will receive a combined oral contraceptive (ethinylestradiol 30 µg + drospirenone 3 mg) once daily for six consecutive months. The intervention aims to regulate menstrual cycles, reduce hyperandrogenic symptoms, and evaluate changes in anxiety and depression scores over time.